SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Attention centers on the FDAs upcoming decision on Capricors deramiocel for Duchenne muscular dystrophy, with traders citing the amended upper-limb data, rare-disease policy discussions and recent launch-related hiring as reasons for optimism. Others caution that approval is uncertain given the prior negative review and continuing questions about the evidence.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Precigens strong quarterly results and rapid PAPZIMEOS commercial uptake are driving attention, with traders highlighting the companys return to profitability and potential for further growth. The upbeat reaction is accompanied by short-squeeze speculation and interest in upcoming PRGN-2009 data and European expansion.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A run to a 52-week high has traders positioning around the expected Q3 earnings report, with BRIUMVIs sales growth supporting optimism. Buyout rumors and heavy short interest are fueling squeeze speculation, though some traders see earnings expectationsnot a confirmed acquisitionas the main driver.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCaths post-TDAPA Medicare add-on could fall sharply after Q1 2027 has fueled concerns about pricing and CorMedix revenue amid a steep selloff. Traders dispute whether DaVitas preliminary outlook signals a broader reimbursement decline, pointing to CMSs published estimate, while others criticize management for not clarifying the potential impact.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs Phase 3 REGAL leukemia trial reached its prespecified 80th death event, triggering final analysis and putting the GPS survival readout at the center of discussion. Traders are divided between optimism about a strong result and concerns about the control arm and trial design, while shares have come under pressure ahead of the binary catalyst.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is under pressure after a steep decline, with traders focused on analyst price-target cuts and uncertainty ahead of its earnings report, as well as concerns about digital-ad growth. Bulls argue the selloff is disconnected from the companys profitability and growth, while bears warn of more downside if results or guidance disappoint; some also point to broader tech-market weakness.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A sharp technology and AI-linked selloffintensified by Intels weak outlook and concerns about returns on heavy AI investmentis driving attention to QQQ. Traders are split between warning of more downside and treating the drop as an oversold dip with potential for a rebound.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

SMH is under pressure amid a semiconductor and tech selloff, as traders question whether heavy AI infrastructure spending will generate adequate returns; weak Intel guidance and concerns about Amazons elevated capex are cited as contributing pressures. The community is divided between expecting a deeper unwind in the AI trade and seeing oversold conditions and technical support as possible grounds for a bounce.

Okta, Inc. engages in the provision of an identity management platform for enterprises. The firm operates through the following geographical segments: United States and International. Its products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Oktas strong quarterly results and raised outlook, alongside expectations that AI agents will increase demand for identity security, fueled a sharp rally. Traders are now debating whether the growth outlook justifies the valuation, with some taking profits or positioning for a pullback.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regenerons stronger-than-expected third-quarter results, supported by growth in Eylea HD and Sanofi collaboration revenue from Dupixent, drove a sharp share-price gain. Traders largely celebrated the earnings beat and breakout, while some pointed to the upcoming cemdisiran decision as another potential catalyst.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

12 Information Technology Stocks Moving In Wednesday's After-Market Session

Gainers

TAO Synergies (NASDAQ:TAOX) stock moved upwards by 10.8% to $4.0 during Wednesday's after-market session. The company's market cap stands at $27.8 million.
Argo Blockchain (NASDAQ:ARBK) shares roseread more...

Best Blockchain Stocks Worth Watching - December 19th

Core Scientific, Globant, Argo Blockchain plc 8.75% Senior Notes due 2026, Figure Technology Solutions, and Bitdeer Technologies Group are the five Blockchain stocks to watch today, according to...

Best Blockchain Stocks Worth Watching - December 17th

Core Scientific, Argo Blockchain plc 8.75% Senior Notes due 2026, Globant, Figure Technology Solutions, and Bitdeer Technologies Group are the five Blockchain stocks to watch today, according to...

Top Blockchain Stocks To Follow Now - December 16th

Core Scientific, Bitdeer Technologies Group, and Argo Blockchain plc 8.75% Senior Notes due 2026 are the three Blockchain stocks to watch today, according to MarketBeat's stock screener tool...

Top Blockchain Stocks To Keep An Eye On - December 13th

Core Scientific, Figure Technology Solutions, Globant, Bitdeer Technologies Group, and Argo Blockchain plc 8.75% Senior Notes due 2026 are the five Blockchain stocks to watch today, according to...

Promising Blockchain Stocks To Watch Now - December 12th

Core Scientific, Figure Technology Solutions, Globant, Argo Blockchain plc 8.75% Senior Notes due 2026, Bitdeer Technologies Group, Mawson Infrastructure Group, and Digi Power X are the seven...

Argo Blockchain (NASDAQ:ARBK) Reaches New 12-Month Low - Here's What Happened

Argo Blockchain (NASDAQ:ARBK) Reaches New 12-Month Low - Should You Sell...

Argo Blockchain Stock Rallies On Potential $40 Million Investment To Upgrade Bitcoin Mining Fleet – Retail Sentiment Bullish

Equity

Under the proposed deal, an initial tranche of $15 million would be disbursed, with additional funding of up to $25 million available over the next 18 months.

Argo Blockchain Plc operates as a blockchain technology company focused on large-scale mining of Bitcoin and other cryptocurrencies. It mines using purpose-built computers to solve cryptographic algorithms in the blockchain in exchange for rewards and fees denominated in the native token of that blockchain network. The company was founded in 2017 and is headquartered in London, the United Kingdom.

Argo Blockchain Plc - ADR

Bearish Sentiment

Argo Blockchain (ARBK) shares surged more than 30% in mid-day trading Monday after the Bitcoin miner announced it had entered into a non-binding term sheet for up to $40 million in senior secured convertible loans.The company said the capital infusion would be used to upgrade its mining fleet at its Baie-Comeau facility in Quebec, bolster its balance sheet, and evaluate merger and acquisition opportunities.Under the proposed deal, an initial tranche of $15 million would be disbursed, with additional funding of up to $25 million available over the next 18 months. The debt financing carries an interest rate of approximately 8%.Argo said the financing is expected to come from up to three multinational institutional investors and will include 30% warrant coverage at a premium to the closing price.As part of the agreement, Argo has granted the investor group a 20-day exclusivity period, with potential extensions depending on progress. The company also agreed to a $150,000 break fee under certain conditions.<figure class="image"><img style="aspect-ratio:1295/285;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2025_03_03_125636_5087bc0946.png" alt="Screenshot 2025-03-03 125636.png" width="1295" height="285"><figcaption>Argo Blockchain retail sentiment and message volume on March 3 as of 12:55 p.m. ET | Source: Stocktwits</figcaption></figure>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/ARBK">Argo’s stock</a> surged into the ‘extremely bullish’ zone from ‘neutral’ a day ago, as chatter jumped to ‘extremely high’ from ‘extremely low’ levels. Some investors took the opportunity to cash in on the rally.<stembedurl>https://stocktwits.com/josg82/message/606516750</stembedurl>Despite the stock's sudden spike, it remains down 13% year-to-date and has lost more than 77% over the past year.Argo Blockchain has recently undergone a change in its management. Former CEO Thomas Chippas stepped down on&nbsp;Feb. 28.Moreover, the company received a Nasdaq delisting warning in January due to its prolonged stock price decline.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tsmc-stock-slides-4-month-low-despite-100-billion-chip-expansion-plan/che0No9Rzy">TSMC Stock Slides To 4-Month Low Even As Trump Reportedly Plans To Announce $100B US Chip Deal – Retail Remains Bullish</a>

Representative image of Bitcoin mining servers. (Photo by Jason Marz/Getty Images)

Argo Blockchain Plc

CoinShares Bitcoin Mining ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$1.55
Prev Close	$1.64
Open	$1.61
Dividend Yield	N/A
50-Day Moving Average	$2.39
Beta	2.47
Avg. Volume	18,278.02
PE Ratio	0.35

52-Week High	$83.16
52-Week Low	$1.55
Market Capitalization	$24M
EPS (Annual)	$5.02
Price to Book	1.70
Revenue Per Employee	$1.2M

Feed

News

Sentiment

Fundamentals

Info

ARBK Fundamentals